Navigation Links
Biodel Reports Third Quarter Fiscal Year 2011 Financial Results
Date:8/4/2011

DANBURY, Conn., Aug. 4, 2011 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) today reported financial results for the third quarter ended June 30, 2011.

Third Quarter Operating Highlights

During Biodel's third quarter of fiscal year 2011, the company:

  • completed Phase 1 testing of two new ultra-rapid-acting formulations of recombinant human insulin, or RHI, for subcutaneous injection;
  • supported investigators at Oregon Health and Sciences University who have initiated a Phase 1 study evaluating these formulations for insulin pump administration;
  • selected multiple analog-based candidate formulations for possible clinical development; and
  • extended the cash runway by reducing near-term RHI purchase requirements and raising approximately $30 million in new capital.

  • Dr. Errol De Souza, president and chief executive officer of Biodel, stated:  "We are continuing to develop and evaluate ultra-rapid-acting human insulin and insulin analog formulations and are making good progress in assessing tolerability and activity in a variety of pre-clinical and clinical settings.  We plan to provide details on the pharmacokinetic, pharmacodynamic and injection site tolerability characteristics of the two RHI-based ultra-rapid-acting formulations from the recently completed subcutaneous injection Phase 1 trial and will update the timelines for completion of the insulin pump trial.  In addition, we have taken a number of steps to extend our cash runway including renegotiation of our RHI supply agreement and raising additional capital from previous and new investors.  These initiatives are helping us create a new generation of ultra-rapid-acting insulin product candidates and sustainable long-term value for all shareholders."

    Third Quarter Financial Results

    Biodel reported a net loss of $4.0 million, or $0.12 per sha
    '/>"/>

    SOURCE Biodel Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study
    2. Biodel to Raise $30 Million Through Registered Direct Offering
    3. Biodel Inc. to Present at 29th Annual JPMorgan Healthcare Conference on January 13th, 2011
    4. Biodel Announces Name Change for Lead Product Candidate
    5. Dyadic International Reports 2011 Second Quarter Financial Results
    6. Vermillion Reports Results for the Second Quarter 2011
    7. ReportsnReports - Needle-Free Drug Delivery Market & Hospital-Acquired Infections (HAI) Diagnostics Market Reports
    8. Dendreon Reports Second Quarter 2011 Financial Results
    9. Cambrex Reports Second Quarter of 2011 Results
    10. Jennerex Reports Positive Mechanistic Proof-of-Concept Clinical Trial Results Using JX-594 to Treat Metastatic Melanoma
    11. Gen-Probe Reports Financial Results for the Second Quarter of 2011
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2014)... BCC Research ( http://www.bccresearch.com ) reveals in ... Industrial Applications , the global market for industrial enzymes ... 2018, registering a five-year compound annual growth rate (CAGR) ... in the detergent enzyme segment with a CAGR of ... influenced almost every sector of industrial activity, ranging from ...
    (Date:7/30/2014)... 2014  Orexigen Therapeutics, Inc. (Nasdaq: OREX ... List of Outstanding Issues (LOI) from the European Medicines ... for the NB32 Marketing Authorization Application (MAA). NB32 (naltrexone ... drug candidate being evaluated for weight loss. ... point were adequately addressed by the Company based in ...
    (Date:7/30/2014)... July 30, 2014   Epic Sciences, Inc. ... novel diagnostics to personalize and advance the treatment and ... Gregory T. Lucier as chairman of Epic,s board ... of Life Technologies (formerly Invitrogen). Mr. Lucier joins Epic,s ... its circulating rare cell analysis platform with special focus ...
    (Date:7/30/2014)... (PRWEB) July 30, 2014 NCERC ... Athmanathan will present his findings on corn stover ... conference this week in Washington, D.C. , ... Energy conference is a testament to the success ... Caupert said. “Thanks to the foresight and vision ...
    Breaking Biology Technology:Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 2NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 3
    ... AMSTERDAM, November 30 Biopharmaceutical company Kiadis,Pharma ... in its,multinational registration clinical trial with ATIR(TM). The study ... after one,year following an allogeneic stem cell transplantation with ... an allogeneic,stem cell transplantation but without having a matched ...
    ... , ... Yongxin Pharmaceuticals, Inc. (OTC Bulletin Board: CYXN; ,China Yongxin,Pharmaceuticals, ... pharmaceuticals in Northeastern China, today announced it has,completed preparation ... , The Chinese government recently ...
    ... NOVATO, Calif., Nov. 30 BioMarin Pharmaceutical Inc. (Nasdaq: ... Drug Administration (FDA) has granted orphan drug designation for ... Lambert Eaton Myasthenic Syndrome (LEMS). 3,4-DAP has previously ... in October 2009, the Committee for Medicinal Products for ...
    Cached Biology Technology:Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM) 2China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 2China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4
    (Date:7/30/2014)... humans figured out how to create colors, nature had ... wings of many different hues, for example. Now scientists ... environmentally friendly way to make colored plastics. Their paper ... of materials rather than dyes, to produce color ... , N. Asger Mortensen, Anders Kristensen and colleagues point ...
    (Date:7/30/2014)... professor from Wayne State University,s College of Engineering ... Science Foundation for the project, "Nanoparticle-directed synthesis of ... Science Foundation, nanotechnology is the creation and utilization ... properties and functions. A major bottleneck in scaling ... that connect different functional materials into one device. ...
    (Date:7/30/2014)... therapies for spinal cord injury (SCI), traumatic brain injury ... great deal has been learned over the past 30 ... factors that regulate axon growth, but this large body ... therapeutics. Prof. Lemmon and his team from University of ... root causes, but a consensus is emerging that one ...
    Breaking Biology News(10 mins):NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2
    ... Eucalyptus trees - or gum trees as they are know - ... system and depositing it their leaves and branches., Scientists from CSIRO ... Nature Communications . "The eucalypt acts as a hydraulic ... and draw up water containing the gold. As the gold is ...
    ... prominence as research reagents in modern biological science labs, ... lot can differ significantly from the next, in terms ... loss of countless hours of research, to say nothing ... antigen is a substance that stimulates the production of ...
    ... Clemson University scientists are working to determine how ... for neurological disorders like Tuberous Sclerosis Complex (TSC). ... growth of tumors in the brain and other vital ... and cognitive impairment that may arise from the abnormal ...
    Cached Biology News:There's gold in them thar trees 2The hitchhiker antigen: Cause for concern? 2Clemson University study points to possible treatment for brain disorders 2
    Rabbit Anti-Human Secretory Carrier Membrane Protein 2 (SCAMP2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: Western Blot...
    Parathyroid Hormone Receptor 2 [PTHR2]...
    ... a proprietary high-performance desalting resin, exclusive to ... characteristics compared to other commercially available resins. ... of protein can be processed, providing exceptional ... salts and other small molecules ( ...
    ... member of the caudal-related homeobox family, is ... proliferation and differentiation in intestinal epithelial cells. ... cells towards the phenotype of differentiated villus ... of the phenotype. Clone CDX2-88 reacts with ...
    Biology Products: